Annual changes to the NASDAQ Biotechnology Index
Last week Nasdaq announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which
went into effect prior to today's market open.
The following 21 securities have been added to the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
AIMT
Aimmune Therapeutics, Inc.
Nasdaq
ARLZ
Aralez Pharmaceuticals Inc.
Nasdaq
AVXS
AveXis, Inc.
Nasdaq
BGNE
BeiGene, Ltd.
Nasdaq
BOLD
Audentes Therapeutics
Nasdaq
CLCD
CoLucid Pharmaceuticals
Nasdaq
CLSD
Clearside Biomedical, Inc.
Nasdaq
CYTK
Cytokinetics, Incorporated
Nasdaq
EDIT
Editas Medicine, Inc.
Nasdaq
GBT
Global Blood Therapeutics
Nasdaq
ITCI
Intra-Cellular Therapies
Nasdaq
LOXO
Loxo Oncology, Inc.
Nasdaq
MNOV
Medicinova Inc
Nasdaq
NERV
Minerva Neurosciences
Nasdaq
NH
NantHealth, Inc.
Nasdaq
NTLA
Intellia Therapeutics, Inc.
Nasdaq
NVCR
NovoCure Limited
Nasdaq
ONVO
Organovo Holdings Inc
Nasdaq
OPK
OPKO Health, Inc.
Nasdaq
PRTK
Paratek Pharmaceuticals, Inc.
Nasdaq
RGNX
REGENXBIO Inc.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
ADHD
Alcobra Ltd.
Nasdaq
ADVM
Adverum Biotechnologies, Inc.
Nasdaq
AFMD
Affimed N.V.
Nasdaq
AGTC
Applied Genetic Technologies Corporation
Nasdaq
ANTH
Anthera Pharmaceuticals, Inc.
Nasdaq
CARA
Cara Therapeutics, Inc.
Nasdaq
CASC
Cascadian Therapeutics, Inc.
Nasdaq
CHMA
Chiasma, Inc.
Nasdaq
CMRX
Chimerix, Inc.
Nasdaq
CNCE
Concert Pharmaceuticals, Inc.
Nasdaq
CXRX
Concordia International Corp.
Nasdaq
DNAI
ProNAi Therapeutics, Inc.
Nasdaq
DRNA
Dicerna Pharmaceuticals, Inc.
Nasdaq
DRRX
DURECT Corporation
Nasdaq
ECYT
Endocyte, Inc.
Nasdaq
EGLT
Egalet Corporation
Nasdaq
FLKS
Flex Pharma, Inc.
Nasdaq
IMDZ
Immune Design Corp.
Nasdaq
IMGN
ImmunoGen, Inc.
Nasdaq
INFI
Infinity Pharmaceuticals, Inc.
Nasdaq
ITEK
Inotek Pharmaceuticals Corporation
Nasdaq
KMPH
KemPharm, Inc.
Nasdaq
LIFE
aTyr Pharma, Inc.
Nasdaq
MNKD
MannKind Corporation
Nasdaq
NDRM
NeuroDerm Ltd.
Nasdaq
NEOS
Neos Therapeutics, Inc.
Nasdaq
OCUL
Ocular Therapeutix, Inc.
Nasdaq
OREX
Orexigen Therapeutics, Inc.
Nasdaq
OSIR
Osiris Therapeutics, Inc.
Nasdaq
OVAS
OvaScience Inc.
Nasdaq
QURE
uniQure N.V.
Nasdaq
RGLS
Regulus Therapeutics Inc.
Nasdaq
SCLN
SciClone Pharmaceuticals, Inc.
Nasdaq
TKAI
Tokai Pharmaceuticals, Inc.
Nasdaq
TTPH
Tetraphase Pharmaceuticals, Inc.
Nasdaq
VTL
Vital Therapies, Inc.
Nasdaq
ZFGN
Zafgen, Inc.
The Top 5 Most-Read Gastroenterology Articles of 2024
December 21st 2024The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the year, while FDA and European approvals for ustekinumab biosimilars are set to improve access and reduce costs for patients with Crohn disease and ulcerative colitis.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.